Rhythm's $750M Deal Clouds a Clean Q3 Beat
Rhythm Pharmaceuticals delivered a 17.5% earnings beat in Q3, its fourth consecutive quarter of outperformance, yet shares fell 10% following the announcement. The market's concern centered on a $750
Rhythm's $750M Deal Clouds a Clean Q3 Beat
NEW YORK, November 6 —
Rhythm Pharmaceuticals, Inc. (RYTM) delivered its largest earnings beat in four consecutive quarters, 17.5% above estimates, yet shares fell roughly 10% in the following session, a reaction that had little to do with the income statement. What drove the sell-off was what came alongside the results: an amended royalty structure on bivamelagon, the company's lead pipeline candidate, and $750 million in new financing, both announced November 3 alongside the quarterly 8-K filing.
- Q3 2026 EPS beat: -$0.61 actual vs. -$0.74 estimated, a 17.5% outperformance, fourth consecutive quarterly beat.
- Trailing twelve-month revenue up 79.6% year-over-year to $0.28 billion; gross margin at 88.2%.
- Net insider selling totals $28.80 million over 90 days ending November 2026; zero insider purchases recorded.
What the Deal Rewrites
Rhythm sells IMCIVREE (setmelanotide), an MC4R agonist approved for rare genetic obesity disorders, POMC deficiency, LEPR deficiency, Bardet-Biedl syndrome, and Alström syndrome, a narrow but fast-growing commercial franchise with 79.6% revenue growth. Bivamelagon, an oral small-molecule MC4R agonist in Phase 2 trials, is the company's next commercial target. The amendment, however, changes the terms governing that asset's future economics. Full terms weren't disclosed in available filings; reports named the licensing counterparty only partially. Raising $750 million simultaneously suggests the financing and the royalty renegotiation are linked, that the new capital came at a cost measured in bivamelagon's long-run upside.
The Selling Pattern Preceded the Verdict
Five C-suite executives sold a combined $28.80 million in shares in the 90 days before the earnings release, with no recorded purchases. EVP Jennifer Kayden Lee sold 75,834 shares at $117.38 on August 13, the largest single transaction, generating approximately $8.90 million. CFO Hunter C. Smith followed on August 31 with roughly $6.62 million in sales across three tranches at $104.59, $106.20. CEO David P. Meeker sold 50,000 shares on September 14 at $101.75, $105.19, for approximately $5.13 million, a price range nearly identical to where RYTM trades today at $105.02. Executives closer to the commercial operation cleared out at $111, $119; the CEO exited closer to current levels, two months later.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| RYTM | $7.3B | n/a | +4.7% |
| PTGX | $8.8B | n/a | +70.1% |
| MIRM | $6.1B | n/a | +37.3% |
| KRYS | $8.9B | 32.9x | +51.7% |
| ANAB | $1.4B | 10.0x | +72.4% |
| KYMR | $10.9B | n/a | +118.4% |
What Resolves the Contradiction
Rhythm's near-term commercial story remains intact: IMCIVREE expanded its U.S. and Japan market presence in Q3, the beat-and-raise pattern across four consecutive quarters signals genuine commercial momentum, and five additional Phase 3 indications for setmelanotide offer a runway that doesn't depend on bivamelagon. Operating cash flow remains -$82 million trailing twelve months despite 88.2% gross margins, so the $750 million financing addresses a real need. The 10% discount the market applied reflects one unknown: the amended royalty terms. When those terms surface in a fuller filing, they become the figure that either validates the deal or confirms the market's read. Run the free Rhythm Pharmaceuticals, Inc. deep-dive →
Current fundamentals, valuation and filing history for Rhythm Pharmaceuticals, Inc. (RYTM) are tracked on its Basis Report page.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Why did Rhythm stock fall after beating earnings?
Rhythm beat Q3 estimates by 17.5%, but the market reacted negatively to a $750M financing coupled with amended royalty terms on the pipeline drug bivamelagon. The full details of the royalty amendment were not disclosed, leaving investors uncertain about the deal's impact on the company's long-term economics.
What is bivamelagon?
Bivamelagon is Rhythm's next commercial ambition after IMCIVREE, an oral small-molecule MC4R agonist currently in Phase 2 trials. The company recently amended the royalty structure on this asset as part of a $750M financing deal announced alongside Q3 results.
Did Rhythm executives sell stock before the announcement?
Yes, five C-suite executives sold $28.80 million in shares over 90 days preceding the earnings release, with zero insider purchases recorded. EVP Jennifer Kayden Lee made the largest sale at $8.90 million, followed by CFO Hunter C. Smith and CEO David P. Meeker.
What does Rhythm make?
Rhythm makes IMCIVREE (setmelanotide), an MC4R agonist approved for rare genetic obesity disorders including POMC deficiency, LEPR deficiency, Bardet-Biedl syndrome, and Alström syndrome. Q3 revenue growth reached 79.6% year-over-year with trailing twelve-month revenue of $0.28 billion and gross margin of 88.2%.
Why did Rhythm need the $750M financing?
Despite high gross margins of 88.2%, Rhythm's trailing twelve-month operating cash flow was negative $82 million. The financing addressed this real cash need, though it came coupled with amended royalty terms that reduced the company's long-term economics on bivamelagon.
Rhythm Pharmaceuticals beat Q3 2026 EPS estimates by 17.5% — its fourth consecutive quarterly beat — yet shares fell roughly 10% in the following session. On the same day as the earnings release, the company announced it had amended the royalty structure on its key pipeline drug bivamelagon and secured $750 million in new financing, leaving investors to weigh accelerating IMCIVREE revenue growth against deal terms that may reshape the drug's long-term economics.